Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedCorcept Therapeutics Inc (CORT) Social Sentiment
CORT Social Sentiment Analysis
Social media sentiment analysis for Corcept Therapeutics Inc (CORT). Track bullish and bearish sentiment, mention volume, and BuzzScore trends from StockTwits and Reddit. Social sentiment provides a crowd-sourced view of investor confidence in CORT.
Current stock price: $51.42. Market cap: $5.47B. This page displays sentiment timelines, bullish vs bearish ratios, total mention counts, peak BuzzScore data, and source breakdowns for CORT. The sentiment data is updated regularly to reflect the latest social media activity.
Social sentiment is one of many signals to consider when evaluating a stock. High bullish sentiment combined with strong fundamentals may reinforce a buy thesis. Use GoodMoat's sentiment tracking alongside quality analysis, financial data, and valuation models to make well-informed investment decisions about Corcept Therapeutics Inc.